Targeted immune cell therapy for solid tumors after surgery and chemo
Part of Cancer, Immune system & allergy clinical trials.
This trial tests a new type of immune cell therapy (dendritic cells) that is designed to target specific proteins found on cancer cells. It is for people with certain solid tumors who have already had surgery and at least 4 cycles of standard chemotherapy after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old and weigh at least 88 lbs (40 kg).
- You have been diagnosed with a solid tumor such as pancreatic, colorectal, or stomach cancer.
- You had surgery to remove the tumor and completed at least 4 cycles of chemotherapy after surgery.
- Your tumor tests positive for at least one of these proteins: TERT, P53, KRAS, or Survivin.
- You have good organ and bone marrow function (kidney, liver, heart, and blood counts are adequate).
- You have not had any prior treatment with dendritic cell therapy or other immune cell therapies.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy, DCTY1102, for people with advanced solid tumors like pancreatic, colorectal, or lung cancer who have tried other treatments. It uses your own immune cells that are modified to target a specific genetic change in your tumor.
This trial tests a new immune cell treatment called Super DC cells to see if it can stop tumors from coming back after they have been surgically removed. It is for people with solid tumors who have had complete removal of the cancer and show no signs of remaining disease on scans.
This trial tests a new type of immune cell therapy (gamma-delta T cells that have been modified to target PD-1) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if these cells can help your immune system fight the cancer.
This trial tests a personalized vaccine made from your own cells to help your immune system attack tumor-specific targets. It may be an option if standard treatments have stopped working or caused side effects you can't tolerate.
This trial tests a personalized cell therapy (tumor polypeptide DC-CTL) for adults with solid tumors such as colorectal, lung, or breast cancer. The goal is to see if infusing your own immune cells trained to attack cancer can help control the disease.
This trial tests a new type of cell therapy (CAR-T and targeted DC cells) for people with advanced solid tumors that have specific proteins. It aims to see if these immune cells can shrink tumors or slow their growth.
Hear when a new Solid Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.